EVOTEC SE

EVT

Delayed - 08/19 11:44:00 am
25.88EUR	-1.97%

Turn to zoom

Prev.	25.88000000
Open	26.08000000
High	26.41000000
Low	25.71000000
Volume	269 261

2d ago	Evotec : PAN-TB Collaboration to Advance Investigational Tuberculosis Drug...
7d ago	Evotec SE reports results for the first half-year 2022 and provides...
7d ago	EVOTEC : Receives a Buy rating from Warburg Research
7d ago	EVOTEC : Buy rating from Deutsche Bank

	Short Term	Mid-Term	Long Term
Trend	Neutral	Neutral	Bearish
Resistance	29,1	29,1	31,0
Spread/Res.	-11%	-11%	-17%
Spread/Supp.	6,9%	23%	18%
Support	24,2	21,1	21,8

Sales 2022	730 M 732 M 732 M
Net income 2022	-33,5 M -33,7 M -33,7 M
Net cash 2022	62,0 M 62,2 M 62,2 M
P/E ratio 2022	235x
Yield 2022	-

Capitalization	4 573 M 4 591 M 4 591 M
EV / Sales 2022	6,18x
EV / Sales 2023	5,40x
Nbr of Employees	4 521
Free-Float	86,9%

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture...

Sector :

Other Biotechnology & Medical Research

Calendar :

2022-09-06 Presentation

Trading Rating :

Investor Rating :

Sell Buy
Mean consensus	OUTPERFORM
Number of Analysts	9
Last Close Price	25,88 €
Average target price	37,33 €
Spread / Average Target	44,3%